What's in Impax Laboratories, LLC's pipeline?

Impax Laboratories, LLC has 14 drugs in our index: 2 marketed, 0 filed, 5 in Phase 3, 5 in Phase 2, 2 in Phase 1.

Which companies overlap with Impax Laboratories, LLC's portfolio?

Top competitors by shared drug class: Alexza Pharmaceuticals, Inc., Alza Corporation, DE, USA, Amsterdam UMC, location VUmc, Assistance Publique Hopitaux De Marseille, B. Braun Melsungen AG.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/impax-laboratories-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Impax Laboratories, LLC — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impax Laboratories, LLC pipeline: 2 marketed, 0 filed, 5 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 5 Phase 3 5 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
CLE	CLE	marketed	Dopamine replacement therapy / Levodopa combination	Dopamine pathway; decarboxylase inhibition	Neurology
CREXONT ER	CREXONT ER	marketed	First-generation cephalosporin antibiotic	Penicillin-binding proteins (PBPs)	Infectious Disease
IPX203	IPX203	phase 3	Opioid analgesic with abuse-deterrent properties	Mu opioid receptor (morphine component); opioid receptors (naltrexone component)	Pain Management
Placebo ZNS	Placebo ZNS	phase 3	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase	Neurology
IPX203 ER CD-LD	IPX203 ER CD-LD	phase 3	Dopaminergic agent; levodopa/carbidopa combination	Dopamine pathway; aromatic L-amino acid decarboxylase inhibition	Neurology
IR CD-LD	IR CD-LD	phase 3	Dopamine replacement therapy / Decarboxylase inhibitor combination	Dopamine pathway; carbidopa inhibits aromatic L-amino acid decarboxylase	Neurology
IPX066	IPX066	phase 3	Dopamine replacement therapy; extended-release levodopa/carbidopa combination	Dopamine pathway (via levodopa conversion to dopamine)	Neurology

Therapeutic area mix

Neurology · 6
Attention Deficit Hyperactivity Disorder (ADHD) · 1
Infectious Disease · 1
Pain Management · 1
Psychiatry · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alexza Pharmaceuticals, Inc. · 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class
Amsterdam UMC, location VUmc · 1 shared drug class
Assistance Publique Hopitaux De Marseille · 1 shared drug class
B. Braun Melsungen AG · 1 shared drug class
Eisai Korea Inc. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
· 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Impax Laboratories, LLC:

Cite this brief

Drug Landscape (2026). Impax Laboratories, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/impax-laboratories-llc. Accessed 2026-06-10.